PSMD1 and non-small cell lung carcinoma: Currently, S-1 has demonstrated activity against a broad spectrum of solid tumors, such as gastric cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, bile duct cancer, breast cancer, and colon cancer.